ATE407138T1 - Verfahren zur herstellung interferierender rna- moleküle in säugetierzellen und therapeutische anwendungen solcher moleküle - Google Patents

Verfahren zur herstellung interferierender rna- moleküle in säugetierzellen und therapeutische anwendungen solcher moleküle

Info

Publication number
ATE407138T1
ATE407138T1 AT03707861T AT03707861T ATE407138T1 AT E407138 T1 ATE407138 T1 AT E407138T1 AT 03707861 T AT03707861 T AT 03707861T AT 03707861 T AT03707861 T AT 03707861T AT E407138 T1 ATE407138 T1 AT E407138T1
Authority
AT
Austria
Prior art keywords
molecules
interfering rna
therapeutic applications
mammal cells
rna molecules
Prior art date
Application number
AT03707861T
Other languages
English (en)
Inventor
John Rossi
Nan-Sook Lee
Original Assignee
Hope City
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27734609&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE407138(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hope City filed Critical Hope City
Application granted granted Critical
Publication of ATE407138T1 publication Critical patent/ATE407138T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111—General methods applicable to biologically active non-coding nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
    • C12N15/1132—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses against retroviridae, e.g. HIV
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/111—Antisense spanning the whole gene, or a large part of it
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/53—Physical structure partially self-complementary or closed
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2330/00—Production
    • C12N2330/30—Production chemically synthesised
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/178—Oligonucleotides characterized by their use miRNA, siRNA or ncRNA

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Plant Pathology (AREA)
  • Virology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • AIDS & HIV (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AT03707861T 2002-02-14 2003-02-13 Verfahren zur herstellung interferierender rna- moleküle in säugetierzellen und therapeutische anwendungen solcher moleküle ATE407138T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US35612702P 2002-02-14 2002-02-14

Publications (1)

Publication Number Publication Date
ATE407138T1 true ATE407138T1 (de) 2008-09-15

Family

ID=27734609

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03707861T ATE407138T1 (de) 2002-02-14 2003-02-13 Verfahren zur herstellung interferierender rna- moleküle in säugetierzellen und therapeutische anwendungen solcher moleküle

Country Status (9)

Country Link
US (6) US7820632B2 (de)
EP (1) EP1483281B2 (de)
JP (1) JP2005527198A (de)
AT (1) ATE407138T1 (de)
AU (1) AU2003209128B2 (de)
CA (1) CA2476530A1 (de)
DE (1) DE60323340D1 (de)
ES (1) ES2312753T5 (de)
WO (1) WO2003068797A1 (de)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2370628A1 (en) * 1999-04-21 2000-10-26 American Home Products Corporation Methods and compositions for inhibiting the function of polynucleotide sequences
US20040138168A1 (en) * 1999-04-21 2004-07-15 Wyeth Methods and compositions for inhibiting the function of polynucleotide sequences
US20070026394A1 (en) 2000-02-11 2007-02-01 Lawrence Blatt Modulation of gene expression associated with inflammation proliferation and neurite outgrowth using nucleic acid based technologies
ATE450621T2 (de) 2000-03-30 2009-12-15 Whitehead Biomedical Inst Mediatoren von rns-interferenz, die rns- sequenzspezifisch sind
KR100872437B1 (ko) * 2000-12-01 2008-12-05 막스-플랑크-게젤샤프트 츄어 푀르더룽 데어 비쎈샤프텐 에.파우. Ｒｎａ 간섭을 매개하는 작은 ｒｎａ 분자
US9994853B2 (en) 2001-05-18 2018-06-12 Sirna Therapeutics, Inc. Chemically modified multifunctional short interfering nucleic acid molecules that mediate RNA interference
US7517864B2 (en) 2001-05-18 2009-04-14 Sirna Therapeutics, Inc. RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA)
US20050148530A1 (en) 2002-02-20 2005-07-07 Sirna Therapeutics, Inc. RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA)
EP3415625A1 (de) 2002-02-01 2018-12-19 Life Technologies Corporation Doppelsträngige oligonukleotide
US20060009409A1 (en) 2002-02-01 2006-01-12 Woolf Tod M Double-stranded oligonucleotides
WO2003064621A2 (en) 2002-02-01 2003-08-07 Ambion, Inc. HIGH POTENCY siRNAS FOR REDUCING THE EXPRESSION OF TARGET GENES
WO2003068797A1 (en) 2002-02-14 2003-08-21 City Of Hope Methods for producing interfering rna molecules in mammalian cells and therapeutic uses for such molecules
AU2003207708A1 (en) * 2002-02-20 2003-09-09 Sirna Therapeutics, Inc. Rna interference mediated inhibition of map kinase genes
US9181551B2 (en) 2002-02-20 2015-11-10 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
US9657294B2 (en) 2002-02-20 2017-05-23 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
US20030180756A1 (en) * 2002-03-21 2003-09-25 Yang Shi Compositions and methods for suppressing eukaryotic gene expression
GB0212302D0 (en) * 2002-05-28 2002-07-10 Isis Innovation Method of selecting targets for gene silencing by RNA interference
US20040248094A1 (en) * 2002-06-12 2004-12-09 Ford Lance P. Methods and compositions relating to labeled RNA molecules that reduce gene expression
US20100075423A1 (en) * 2002-06-12 2010-03-25 Life Technologies Corporation Methods and compositions relating to polypeptides with rnase iii domains that mediate rna interference
AU2003276666A1 (en) * 2002-06-12 2003-12-31 Ambion, Inc. Methods and compositions relating to polypeptides with rnase iii domains that mediate rna interference
US20080274989A1 (en) 2002-08-05 2008-11-06 University Of Iowa Research Foundation Rna Interference Suppression of Neurodegenerative Diseases and Methods of Use Thereof
US20050255086A1 (en) * 2002-08-05 2005-11-17 Davidson Beverly L Nucleic acid silencing of Huntington's Disease gene
US20040023390A1 (en) * 2002-08-05 2004-02-05 Davidson Beverly L. SiRNA-mediated gene silencing with viral vectors
US20040241854A1 (en) * 2002-08-05 2004-12-02 Davidson Beverly L. siRNA-mediated gene silencing
US20050042646A1 (en) * 2002-08-05 2005-02-24 Davidson Beverly L. RNA interference suppresion of neurodegenerative diseases and methods of use thereof
US20050106731A1 (en) * 2002-08-05 2005-05-19 Davidson Beverly L. siRNA-mediated gene silencing with viral vectors
WO2004014933A1 (en) * 2002-08-07 2004-02-19 University Of Massachusetts Compositions for rna interference and methods of use thereof
US7892793B2 (en) 2002-11-04 2011-02-22 University Of Massachusetts Allele-specific RNA interference
AU2003298718A1 (en) * 2002-11-22 2004-06-18 University Of Massachusetts Modulation of hiv replication by rna interference
ES2712695T3 (es) 2003-06-02 2019-05-14 Univ Massachusetts Métodos y composiciones para controlar la eficacia de la silenciación del ARN
US7750144B2 (en) 2003-06-02 2010-07-06 University Of Massachusetts Methods and compositions for enhancing the efficacy and specificity of RNA silencing
AU2004252442B2 (en) * 2003-06-02 2010-04-08 University Of Massachusetts Methods and compositions for enhancing the efficacy and specificity of FNAi
US8680063B2 (en) 2003-09-12 2014-03-25 University Of Massachusetts RNA interference for the treatment of gain-of-function disorders
WO2005027980A1 (en) * 2003-09-12 2005-03-31 University Of Massachusetts Rna interference for the treatment of gain-of-function disorders
JPWO2005032561A1 (ja) * 2003-10-03 2006-12-14 独立行政法人理化学研究所 ＨＩＶ−Ｖｐｒの機能に関する発明
US20060134787A1 (en) 2004-12-22 2006-06-22 University Of Massachusetts Methods and compositions for enhancing the efficacy and specificity of single and double blunt-ended siRNA
US20050227940A1 (en) * 2004-01-23 2005-10-13 City Of Hope Amplifying interfering RNA (RNAi) expression and effects
JP2007523649A (ja) 2004-02-10 2007-08-23 サーナ・セラピューティクス・インコーポレイテッド 多機能短鎖干渉核酸（多機能ｓｉＮＡ）を用い、ＲＮＡ干渉を介した遺伝子発現の阻害
US10508277B2 (en) 2004-05-24 2019-12-17 Sirna Therapeutics, Inc. Chemically modified multifunctional short interfering nucleic acid molecules that mediate RNA interference
EP1799826B1 (de) * 2004-09-29 2009-08-12 Children's Memorial Hospital siRNA-VERMITTELTES GEN-SILENCING VON ALPHA-SYNUKLEIN
US20060142228A1 (en) * 2004-12-23 2006-06-29 Ambion, Inc. Methods and compositions concerning siRNA's as mediators of RNA interference
US7919583B2 (en) 2005-08-08 2011-04-05 Discovery Genomics, Inc. Integration-site directed vector systems
JP2009504782A (ja) 2005-08-18 2009-02-05 アルナイラム ファーマシューティカルズ インコーポレイテッド 神経疾患を治療するための方法および組成物
JP5226179B2 (ja) * 2005-09-22 2013-07-03 オリンパス株式会社 生物学的相互作用の解析方法および試薬キット
WO2008094516A2 (en) 2007-01-29 2008-08-07 City Of Hope Multi-targeting short interfering rnas
WO2008143774A2 (en) * 2007-05-01 2008-11-27 University Of Massachusetts Methods and compositions for locating snp heterozygosity for allele specific diagnosis and therapy
CN101121939B (zh) * 2007-05-15 2011-06-22 西安交通大学 siRNA筛选系统的通用性绿色荧光蛋白融合靶基因表达载体
US8030290B2 (en) 2007-12-07 2011-10-04 City Of Hope Cell-type specific aptamer-siRNA delivery system for HIV-1 Therapy
US8309791B2 (en) 2008-07-16 2012-11-13 Recombinectics, Inc. Method for producing a transgenic pig using a hyper-methylated transposon
EP3766975A1 (de) 2010-10-29 2021-01-20 Sirna Therapeutics, Inc. Rna-interferenz-vermittelte inhibition von genexpression unter verwendung kurzer interferierender nukleinsäure (sina)
EP3971283A1 (de) * 2014-02-27 2022-03-23 Monsanto Technology LLC Zusammensetzungen und verfahren zur stellengerichteten genommodifikation

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2003A (en) * 1841-03-12 Improvement in horizontal windivhlls
KR960704033A (ko) * 1993-07-19 1996-08-31 다니엘 엘. 캐시앙 인간 면역결핍 바이러스에 대한 활성을 갖는 올리고뉴클레오티드(Oligonucleotides with Activity against Humand Immunodeficiency Virus)
US5624803A (en) * 1993-10-14 1997-04-29 The Regents Of The University Of California In vivo oligonucleotide generator, and methods of testing the binding affinity of triplex forming oligonucleotides derived therefrom
US6506559B1 (en) * 1997-12-23 2003-01-14 Carnegie Institute Of Washington Genetic inhibition by double-stranded RNA
AUPP249298A0 (en) * 1998-03-20 1998-04-23 Ag-Gene Australia Limited Synthetic genes and genetic constructs comprising same I
WO2000044914A1 (en) * 1999-01-28 2000-08-03 Medical College Of Georgia Research Institute, Inc. Composition and method for in vivo and in vitro attenuation of gene expression using double stranded rna
CA2370628A1 (en) 1999-04-21 2000-10-26 American Home Products Corporation Methods and compositions for inhibiting the function of polynucleotide sequences
US20030084471A1 (en) * 2000-03-16 2003-05-01 David Beach Methods and compositions for RNA interference
ATE450621T2 (de) * 2000-03-30 2009-12-15 Whitehead Biomedical Inst Mediatoren von rns-interferenz, die rns- sequenzspezifisch sind
US20020173478A1 (en) * 2000-11-14 2002-11-21 The Trustees Of The University Of Pennsylvania Post-transcriptional gene silencing by RNAi in mammalian cells
CH695778A5 (de) * 2000-11-29 2006-08-31 Hoffmann La Roche Hemmung der Transkription eines Zielgens in einer Zelle oder in Geweben.
KR100872437B1 (ko) * 2000-12-01 2008-12-05 막스-플랑크-게젤샤프트 츄어 푀르더룽 데어 비쎈샤프텐 에.파우. Ｒｎａ 간섭을 매개하는 작은 ｒｎａ 분자
ES2609014T3 (es) * 2001-07-12 2017-04-18 University Of Massachusetts Producción in vivo de ARN de interferencia pequeños que median el silenciamiento génico
US20030198627A1 (en) * 2001-09-01 2003-10-23 Gert-Jan Arts siRNA knockout assay method and constructs
AU2002326906C1 (en) 2001-09-13 2009-01-29 California Institute Of Technology Method for expression of small antiviral RNA molecules within a cell
WO2003046173A1 (en) * 2001-11-28 2003-06-05 Center For Advanced Science And Technology Incubation, Ltd. siRNA EXPRESSION SYSTEM AND PROCESS FOR PRODUCING FUNCTIONAL GENE-KNOCKDOWN CELLS AND THE LIKE USING THE SAME
JP3642573B2 (ja) 2001-11-28 2005-04-27 株式会社東京大学Ｔｌｏ ｓｉＲＮＡ発現システムおよびこれを用いた機能遺伝子ノックダウン細胞等の生産方法
GB0130955D0 (en) * 2001-12-24 2002-02-13 Cancer Res Ventures Expression system
US7294504B1 (en) * 2001-12-27 2007-11-13 Allele Biotechnology & Pharmaceuticals, Inc. Methods and compositions for DNA mediated gene silencing
WO2003068797A1 (en) 2002-02-14 2003-08-21 City Of Hope Methods for producing interfering rna molecules in mammalian cells and therapeutic uses for such molecules
EP1634877B1 (de) 2004-08-17 2011-06-22 Simpson Biotech Co., Ltd. Mischung und Verbindungen von Mycelien von Antrodia Camphorata und deren Verwendung

Also Published As

Publication number Publication date
ES2312753T5 (es) 2012-12-13
US20150118682A1 (en) 2015-04-30
US20100184207A1 (en) 2010-07-22
US8106181B2 (en) 2012-01-31
EP1483281B1 (de) 2008-09-03
US20110003307A1 (en) 2011-01-06
WO2003068797A1 (en) 2003-08-21
US9181584B2 (en) 2015-11-10
US7820632B2 (en) 2010-10-26
DE60323340D1 (de) 2008-10-16
EP1483281A1 (de) 2004-12-08
US20120095080A1 (en) 2012-04-19
US20040096843A1 (en) 2004-05-20
US8076071B2 (en) 2011-12-13
JP2005527198A (ja) 2005-09-15
US20140206751A1 (en) 2014-07-24
ES2312753T3 (es) 2009-03-01
EP1483281A4 (de) 2006-07-19
AU2003209128A1 (en) 2003-09-04
EP1483281B2 (de) 2012-09-05
US8927519B2 (en) 2015-01-06
CA2476530A1 (en) 2003-08-21
AU2003209128B2 (en) 2008-05-15

Similar Documents

Publication Publication Date Title
DE60323340D1 (de) Verfahren zur herstellung interferierender rna-moleküle in säugetierzellen und therapeutische anwendungen solcher moleküle
ATE405644T1 (de) Verfahren zur herstellung und reinigung von erythropoietin
ATE353361T1 (de) Gezielten modifikation der chromatinstruktur
CY1106821T1 (el) Μεθοδος για την καλλιεργεια υποκαταστατου χονδρου και βιολογικη μητρα, παραγομενη συμφωνα με τη μεθοδο αυτη
DE502005002356D1 (de) Neue 2-benzylaminodihydropteridinone, verfahren zu deren herstellung und deren verwendung als arzneimittel
SG149061A1 (en) Definitive endoderm
DE60238058D1 (de) Verwendung von lysyloxydase inhibitoren zur zellkultur und gewebeaufbau
ATE296094T1 (de) Stickstoffmonoxid bildende zusammensetzungen zur behandlung von nagelbettinfektionen
DE60314865D1 (de) Verfahren zur herstellung von modifiziertem polymer, danach erhaltenes modifiziertes polymer und kautschukzusammensetzung
ATE549401T1 (de) Rational konstruierte meganukleasen mit veränderter sequenzspezifität und dna- bindungsaffinität
ATE397676T1 (de) Identifikation und verwendung von mirnas zur differenzierung myelogener leukämiezellen
ATE542803T1 (de) Verfahren zur herstellung von dihydrochinazolinen
DE60228846D1 (de) Neue mesogene, verfahren zu deren herstellung und verwendung
DE602004031134D1 (de) Pharmazeutische zusammensetzungen und verfahren zur verwendung von levodopa und carbidopa
BRPI0515684A (pt) formulações de cristais injetáveis ativas de longa duração de metabólitos de estradiol, e métodos de utilização das mesmas
MX2007010045A (es) Pirazolopirimidinas.
DE602005021684D1 (de) Verfahren zur herstellung von pimecrolimus
EP1668125A4 (de) Modifizierte enzyme, verfahren zur herstellung modifizierter enzyme und verwendungen davon
NO20055741L (no) Nye kjemiske forbindelser
TW200507840A (en) Method of treating multiple myeloma
ATE344321T1 (de) Verfahren zur aufreinigung von bakterienzellen und zellbestandteilen
DE60330099D1 (de) Verfahren und Anordnungen zur Herstellung, Feststellung und Übertragung von Identifikatoren
TW200506059A (en) Method for obtaining mastocyte lines from pig tissues and for producing heparin-type molecules
ATE491688T1 (de) Verfahren zur herstellung von 2-substituierten 5- (1-alkylthio)alkylpyridinen
ATE446384T1 (de) Verfahren zur amplifikation von nukleinsäuren mittels promotor-templates

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties